Vor Biopharma (VOR) Accumulated Expenses (2020 - 2026)

Vor Biopharma (VOR) has 7 years of Accumulated Expenses data on file, last reported at $14.7 million in Q1 2026.

• Quarterly Accumulated Expenses rose 701.69% year-over-year to $14.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $14.7 million (up 701.69% YoY) and the FY2025 annual result came in at $19.8 million, up 237.73% from the prior year.
• Accumulated Expenses declined to $14.7 million in Q1 2026 per VOR's latest filing, from $19.8 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $19.8 million in Q4 2025 and bottomed at $1.8 million in Q1 2025.
• The 5-year median for Accumulated Expenses is $5.5 million (2023), against an average of $6.6 million.
• The widest annual swing landed in 2025, when Accumulated Expenses tumbled 65.82%; it then surged 701.69% in 2026.
• Tracing VOR's Accumulated Expenses over 5 years: stood at $4.4 million in 2022, then jumped by 35.25% to $6.0 million in 2023, then retreated by 1.85% to $5.9 million in 2024, then soared by 237.73% to $19.8 million in 2025, then declined by 25.49% to $14.7 million in 2026.
• Per Business Quant, the three latest VOR Accumulated Expenses figures stand at $14.7 million (Q1 2026), $19.8 million (Q4 2025), and $3.0 million (Q3 2025).

Peer Comparison